Clinical data | |
---|---|
Routes of administration | Oral administration |
Drug class | Opioid antagonist; κ-Opioid receptor antagonist |
CVL-354 is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders. [1] [2]
It acts as a selective antagonist of the κ-opioid receptor. [1] [2] The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor. [2] CVL-354 is taken by mouth. [1] It was originated by Pfizer and is under development by Cerevel Therapeutics. [1] As of September 2022, CVL-354 is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders. [1]
Clinical data | |
---|---|
Routes of administration | Oral administration |
Drug class | Opioid antagonist; κ-Opioid receptor antagonist |
CVL-354 is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders. [1] [2]
It acts as a selective antagonist of the κ-opioid receptor. [1] [2] The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor. [2] CVL-354 is taken by mouth. [1] It was originated by Pfizer and is under development by Cerevel Therapeutics. [1] As of September 2022, CVL-354 is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders. [1]